Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Mar;41(3):687–692. doi: 10.1128/aac.41.3.687

In vivo anti-influenza virus activity of a zinc finger peptide.

A K Judd 1, A Sanchez 1, D J Bucher 1, J H Huffman 1, K Bailey 1, R W Sidwell 1
PMCID: PMC163772  PMID: 9056014

Abstract

Matrix protein (M1) is a major structural protein of influenza virus, and it inhibits its own polymerase. A 19-amino-acid peptide, corresponding to a zinc finger region of the M1 sequence of influenza virus strain A/PR/8/34 (H1N1), centered around amino acids 148 to 166, was synthesized. This peptide, designated peptide 6, represents a zinc finger which includes a 7-amino-acid loop or finger and a 4-amino-acid tail at the carboxyl terminus, in addition to the 8 amino acids involved in the coordination of Zn. Three experiments were run to evaluate the activity of peptide 6 on infections induced in mice by influenza A/PR/8/34 and A/Victoria/3/75 (H3N2) viruses. Intranasal (i.n.) treatment of the H1N1 virus infection with 30 or 60 mg/kg of body weight/day, three times daily for 5 days, beginning 4 h pre-or 8 h post-virus exposure, was effective in preventing death, reducing the arterial oxygen decline, and inhibiting lung consolidation. Virus titers in the lungs determined on day 5 were reduced by up to 1.5 log10 in treated groups, but considerable variation in the titers of the recovered virus was seen. The H3N2 virus infection was treated i.n. with 30, 60, or 120 mg of peptide 6/kg/day by using the above-mentioned delayed initiation treatment schedule, and similar protection was seen, although lung virus titers were not reduced in the day-5 assay. Peptide 6 was well tolerated at doses up to 60 mg/kg/day. This zinc finger peptide may provide a new class of antivirals effective against influenza virus.

Full Text

The Full Text of this article is available as a PDF (83.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen H., McCauley J., Waterfield M., Gething M. J. Influenza virus RNA segment 7 has the coding capacity for two polypeptides. Virology. 1980 Dec;107(2):548–551. doi: 10.1016/0042-6822(80)90324-4. [DOI] [PubMed] [Google Scholar]
  2. Bucher D. J., Kharitonenkov I. G., Zakomirdin J. A., Grigoriev V. B., Klimenko S. M., Davis J. F. Incorporation of influenza virus M-protein into liposomes. J Virol. 1980 Nov;36(2):586–590. doi: 10.1128/jvi.36.2.586-590.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Calnan B. J., Tidor B., Biancalana S., Hudson D., Frankel A. D. Arginine-mediated RNA recognition: the arginine fork. Science. 1991 May 24;252(5009):1167–1171. doi: 10.1126/science.252.5009.1167. [DOI] [PubMed] [Google Scholar]
  4. Clemens K. R., Wolf V., McBryant S. J., Zhang P., Liao X., Wright P. E., Gottesfeld J. M. Molecular basis for specific recognition of both RNA and DNA by a zinc finger protein. Science. 1993 Apr 23;260(5107):530–533. doi: 10.1126/science.8475383. [DOI] [PubMed] [Google Scholar]
  5. Hayden F. G., Belshe R. B., Clover R. D., Hay A. J., Oakes M. G., Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989 Dec 21;321(25):1696–1702. doi: 10.1056/NEJM198912213212502. [DOI] [PubMed] [Google Scholar]
  6. Hayden F. G., Cote K. M., Douglas R. G., Jr Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother. 1980 May;17(5):865–870. doi: 10.1128/aac.17.5.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hayden F. G., Gwaltney J. M., Jr, Van de Castle R. L., Adams K. F., Giordani B. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother. 1981 Feb;19(2):226–233. doi: 10.1128/aac.19.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nasser E. H., Judd A. K., Sanchez A., Anastasiou D., Bucher D. J. Antiviral activity of influenza virus M1 zinc finger peptides. J Virol. 1996 Dec;70(12):8639–8644. doi: 10.1128/jvi.70.12.8639-8644.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ryan D. M., Ticehurst J., Dempsey M. H., Penn C. R. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother. 1994 Oct;38(10):2270–2275. doi: 10.1128/aac.38.10.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Scholtissek C., Faulkner G. P. Amantadine-resistant and -sensitive influenza A strains and recombinants. J Gen Virol. 1979 Sep;44(3):807–815. doi: 10.1099/0022-1317-44-3-807. [DOI] [PubMed] [Google Scholar]
  11. Sidwell R. W., Huffman J. H., Gilbert J., Moscon B., Pedersen G., Burger R., Warren R. P. Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrob Agents Chemother. 1992 Feb;36(2):473–476. doi: 10.1128/aac.36.2.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(4050):705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
  13. Winter G., Fields S. Cloning of influenza cDNA ino M13: the sequence of the RNA segment encoding the A/PR/8/34 matrix protein. Nucleic Acids Res. 1980 May 10;8(9):1965–1974. doi: 10.1093/nar/8.9.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ye Z. P., Baylor N. W., Wagner R. R. Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Virol. 1989 Sep;63(9):3586–3594. doi: 10.1128/jvi.63.9.3586-3594.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ye Z. P., Pal R., Fox J. W., Wagner R. R. Functional and antigenic domains of the matrix (M1) protein of influenza A virus. J Virol. 1987 Feb;61(2):239–246. doi: 10.1128/jvi.61.2.239-246.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ye Z., Wagner R. R. Down-regulation of vesicular stomatitis virus transcription by the matrix protein of influenza virus. J Gen Virol. 1992 Mar;73(Pt 3):743–748. doi: 10.1099/0022-1317-73-3-743. [DOI] [PubMed] [Google Scholar]
  17. Zvonarjev A. Y., Ghendon Y. Z. Influence of membrane (M) protein on influenza A virus virion transcriptase activity in vitro and its susceptibility to rimantadine. J Virol. 1980 Feb;33(2):583–586. doi: 10.1128/jvi.33.2.583-586.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES